MYD88 and ovarian carcinoma: In human epithelial ovarian cancer tested on tissue samples of 500 patients by immunohistochemistry, it was shown that expression of TLR4 and MyD88 predicts poorer overall patient survival apparently due to favoring inflammatory microenvironment at the site of tumor growth (Li et al. 2016).